Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Alnylam Pharmaceuticals Inc

Current price
150.06 USD +1.66 USD (+1.12%)
Last closed 147.76 USD
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 18 690 457 600 USD
Yield for 12 month -19.52 %
21.11.2021 - 28.11.2021

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. Address: 675 West Kendall Street, Cambridge, MA, United States, 02142

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
MSFT MSFT Microsoft


WallStreet Target Price

222.68 USD

P/E ratio

Dividend Yield

Current Year

+1 828 292 000 USD

Last Year

+1 037 418 000 USD

Current Quarter

+494 333 000 USD

Last Quarter

+439 718 000 USD

Current Year

+1 517 886 000 USD

Last Year

+868 601 000 USD

Current Quarter

+428 357 000 USD

Last Quarter

+353 860 000 USD

Key Figures ALNY

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -122 297 000 USD
Operating Margin TTM -8.79 %
PE Ratio
Return On Assets TTM -3.05 %
PEG Ratio -0.49
Return On Equity TTM -1500.66 %
Wall Street Target Price 222.68 USD
Revenue TTM 2 003 335 040 USD
Book Value -1.73 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY 54.8 %
Dividend Yield
Gross Profit TTM 868 601 000 USD
Earnings per share -2.64 USD
Diluted Eps TTM -2.64 USD
Most Recent Quarter I 2024
Quarterly Earnings Growth YOY
Profit Margin -16.58 %

Dividend Analytics ALNY

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History ALNY

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor
Payout Ratio
Last Split Date
Dividend Date

Stock Valuation ALNY

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 9.6506
Price Sales TTM 10.2709
Enterprise Value EBITDA -81.9647
Price Book MRQ 142.9249

Financials ALNY

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators ALNY

For 52 weeks

141.98 USD 218.88 USD
50 Day MA 149.37 USD
Shares Short Prior Month 2 625 342
200 Day MA 168.26 USD
Short Ratio 5.3
Shares Short 2 540 313
Short Percent 2.32 %

Dynamics of changes in the value of assets




430.16 USD Microsoft Corporation +3.16 (+0.74%)
Detailed analytics

ETF funds



14.70 EUR iShares EURO STOXX Banks 30-15 UCITS ETF (DE) +0.1 (+0.64%)
Detailed analytics



2357.98 USD Gold +6.23 (+0.27%)
Detailed analytics